Hematologic Malignancies and Cellular Therapy

Danielle Marie Brander, MD

Assistant Professor of Medicine

Member of the Duke Cancer Institute

Campus mail 2400 Pratt St Suite 5000, Durham, NC 27710

Phone (919) 668-1000

Email address danielle.brander@duke.edu

In Their Words

Education and Training

Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
M.D., Duke University School of Medicine, 2007

Grants

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies
AN OPEN LABEL PHASE Ia/b DOSE ESCALATION FOLLOWED BY DOSE EXPANSION SAFETY AND TOLERABILITY TRIAL OF CAP 100, A HUMANIZED C C CHEMOKINE RECEPTOR 7 ANTIBODY, ADMINISTERED AS MONOTHERAPY IN SUBJECTS WITH R/R CHRONIC LYMPHOCYTIC LEUKEMIA
A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
A Phase 1, Open-label, study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies after failure of prior standard therapies
BGB-3111-304 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas
An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
DFCI Obinutuzumab and Ibrutinib Protocol # 15-283
A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
A Multi¿Center, Open¿Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Phase III study of ACP-196 vs Ibrutinib in High Risk CLL
Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.

Publications

Stephens, Deborah M., Ken Boucher, Elizabeth Kander, Sameer A. Parikh, Erin M. Parry, Mazyar Shadman, John M. Pagel, et al. “Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.” Haematologica 106, no. 11 (November 1, 2021): 2845–52. https://doi.org/10.3324/haematol.2020.256388.

PMID

33054118

Full Text

Ruppert, Amy S., Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, et al. “Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.” Leukemia 35, no. 10 (October 2021): 2854–61. https://doi.org/10.1038/s41375-021-01342-x.

PMID

34274940

Full Text

Ma, Shuo, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, et al. “Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.” Blood 138, no. 10 (September 9, 2021): 836–46. https://doi.org/10.1182/blood.2020009578.

PMID

34115103

Full Text

Gordon, Max J., Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, et al. “The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 17 (September 2021): 4814–24. https://doi.org/10.1158/1078-0432.ccr-20-3993.

PMID

34168050

Full Text

Kleinstern, Geffen, J Brice Weinberg, Sameer A. Parikh, Esteban Braggio, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, et al. “Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.” Leukemia, July 20, 2021. https://doi.org/10.1038/s41375-021-01344-9.

PMID

34285341

Full Text

Mato, Anthony R., Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, et al. “Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.” Blood 137, no. 20 (May 20, 2021): 2817–26. https://doi.org/10.1182/blood.2020007376.

PMID

33259589

Full Text

Sitlinger, Andrea, Michael A. Deal, Erwin Garcia, Dana K. Thompson, Tiffany Stewart, Grace A. MacDonald, Nicolas Devos, et al. “Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL).” Cells 10, no. 5 (May 11, 2021). https://doi.org/10.3390/cells10051165.

PMID

34064804

Full Text

Slager, Susan L., Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi, Neil E. Kay, et al. “Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.” Blood 137, no. 15 (April 15, 2021): 2046–56. https://doi.org/10.1182/blood.2020006322.

PMID

33512457

Full Text

Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, et al. “Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.” Lancet Haematol 8, no. 4 (April 2021): e254–66. https://doi.org/10.1016/S2352-3026(20)30433-6.

PMID

33631112

Full Text

Eyre, Toby A., Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, et al. “Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.” Haematologica 106, no. 1 (January 1, 2021): 284–87. https://doi.org/10.3324/haematol.2019.241539.

PMID

32079693

Full Text

Danielle Marie Brander, MD

Education and Training

Grants

Publications

Pages